Tagged with Germany

Germany The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion into the US; the antibody-drug conjugate (ADC) specialist Tubulis’ series B2 financing, and Novartis’ deal with biotech MorphoSys.   Germany’s…

Global Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du jour, Saskia Steinacker, senior VP, global head strategy and digital transformation at Bayer, argues that successful AI implementation within Pharma…

Global Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found herself out of a job.  Now, after joining the boards of several biotechs, including Galapagos, Schaffert returns to big pharma,…

Germany The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes Pharma’s plans to spend EUR 25 million euros to enhance its production capabilities.   Eli Lilly plans new 2 billion…

Germany Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while the European Commission is looking at a major overhaul of the EU’s pharmaceutical regulations. Germany, in light of the growing…

Belgium Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the key industrial investments and trends for German companies within Belux and why Belgium should be better known as an investment…

Germany While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team in place. Former Roche Pharma head Bill Anderson is yet to lay out his strategic priorities as CEO of Bayer…

Germany Germany-based pharma and healthcare services group Fresenius has had its share of challenges. After the group’s dialysis division, Fresenius Medical Care (FMC), was hit with a high rate of COVID-19 deaths among patients using its products and other areas of the business were faced with economic headwinds, the group was…

Germany Home to Europe’s largest pharma market, a host of industry giants, a thriving biotech scene, and a public healthcare system undergoing significant reform, Germany is indisputably one of the world’s most important life science nations.   An overview of the pharma industry in Germany. Made with Visme Infographic Maker   The…

Germany In response to a looming deficit of EUR 17 billion, Germany’s new Financial Stabilization of Statutory Health Insurance System Act (GKV-Finanzstabilisierungsgesetz, or GKV-FinStG) is aimed at containing costs in the country’s health insurance system by distributing the financial burden amongst all healthcare stakeholders, yet biopharma companies stand to be hit…

Germany The latest from German pharma, including Merck KGaA’s increased gamble on external innovation, Bayer’s focus supply chain stability, CatalYm’s EUR 50 million series C financing and Boehringer Ingelheim’s deal with California biotech, Surrozen.   German CDMO Rentschler’s chief executive, Frank Mathias, stepping down (Fierce Pharma) After seven years at the…

Global Fortune’s new 50 Most Powerful Women in Business list features four representatives of Big Pharma, as well as a further four from powerful US health insurance corporations.   The annual ranking is based on five criteria: the size and importance of a leader’s business in the global economy, the health…